Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Oseltamivir carboxylate** is the active metabolite of oseltamivir phosphate (marketed as Tamiflu), formed via hepatic hydrolysis after oral administration. It is a potent, selective inhibitor of the influenza virus enzyme neuraminidase, which is essential for viral replication and release from host cells. Oseltamivir carboxylate acts by competitively inhibiting the active site of neuraminidase, thereby halting the spread of infection within the respiratory tract. This leads to reduced viral titers, shortened symptom duration, and lower viral shedding in treated patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oseltamivir carboxylate.